Creative Biolabs Leads the Forefront of iPSC Technology

 Breaking News
  • No posts were found

Creative Biolabs Leads the Forefront of iPSC Technology

August 03
21:42 2022
Creative Biolabs’ stem cell platform offers expertise in the generation, bioprocess scale-up, and differentiation of iPSCs.

New York, USA – August 3, 2022 – Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from somatic cells. iPSC technology has evolved rapidly since its inception in 2006 and has been widely used for disease modeling.

The global iPSC market is expected to grow from $2431.2 million in 2021 to $2640.80 million in 2022 at a compound annual growth rate (CAGR) of 8.6%. Meanwhile, the market is expected to reach $3571.48 million in 2026 at a CAGR of 7.8%, according to the Report Linker.

Creative Biolabs has constructed an advanced platform that offers various iPSC services, including:

• iPSC reprogramming service

• iPSC culture service

• Pluripotency characterization service

• iPSC genome editing service

• iPSC differentiation service

With years of exploration in the iPSC development, Creative Biolabs is dedicated to providing helpful iPSC culture services, including maintenance of iPSC, 3D culture of iPSC, as well as scale-up of iPSC culture.

Researchers at Creative Biolabs have built two unique systems for iPSCs culture, which are the feeder-dependent culture system and the feeder-free culture system. In order to break the bottleneck for mass production of high-quality iPSCs, Creative Biolabs has built a 3D culture system for iPSC expansion and differentiation based on a thermoreversible hydrogel. The 3D culture system enables a long-term and serial expansion of multiple human iPSC lines via a mild process. With these wonderful advantages, the 3D culture system may be useful at various scales, from basic biological research to clinical trials.

Moreover, the use of bioreactor systems has greatly improved the development of dynamic suspension culture. Bioreactor systems can promote the control of iPSC aggregation, avoid the formation of gradients, and improve the mass transfer, thus leading to higher cell density.

With the advanced iPSC development platform, Creative Biolabs offers high-quality iPSC genome editing services. Nowadays, the application of custom-engineered sequence-specific nucleases enables genetic changes in human cells to be easily accessed with much greater efficiency and precision, such as CRISPR/Cas9 and TALEN. iPSC genome editing services at Creative Biolabs can help achieve the following goals:

• Knock out a gene of interest

• Knock in a disease-associated point mutation

• Tag a gene of interest with required reporters

• Reversion to wildtype in disease-derived iPSC line

Explore more top-notch services for stem cell therapy development at https://www.creative-biolabs.com/stem-cell-therapy.

About Creative Biolabs

With professional scientists and years of experience, Creative Biolabs provides high-quality products and services in the field of stem cell therapy development for customers all over the world.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/stem-cell-therapy

Categories